Semaglutide weight loss claims on TikTok: what the data says

What's this video probably claiming?

Based on the hashtags and caption framing, this video almost certainly follows the standard GLP-1 transformation format: a before-and-after visual paired with implied or explicit credit to semaglutide (Ozempic or Wegovy) for significant weight loss. Creators in this genre typically suggest the drug works fast, works for everyone, and requires minimal lifestyle changes beyond taking the injection. There's often a claim, stated or implied, that results seen in 3 to 6 months are typical and sustainable. Some videos in this space also blur the line between Ozempic (approved for type 2 diabetes, 0.5 to 2 mg weekly) and Wegovy (approved for chronic weight management, up to 2.4 mg weekly), treating them as interchangeable. They're not. The doses are different. The approvals are different. The insurance coverage is different.

What does the science actually show?

The clinical evidence for semaglutide in weight management is genuinely strong, which is what makes the social media distortion so frustrating. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants on 2.4 mg weekly semaglutide lost an average of 14.9% body weight over 68 weeks, compared to 2.4% with placebo. That's real. The STEP 5 trial extended follow-up to 104 weeks and showed sustained weight loss with continued treatment. But here's what most TikTok transformation videos skip: roughly one-third of participants in STEP 1 experienced nausea, and 4.5% discontinued due to adverse effects. Weight regain after stopping semaglutide was documented in the STEP 4 withdrawal trial (Rubino et al., 2021, JAMA), where participants regained about two-thirds of lost weight within a year of discontinuation. That part rarely makes the caption.

Where does the social media noise diverge from clinical reality?

Several gaps between TikTok narratives and clinical data are worth calling out directly. First, timelines. Transformation videos often compress months of gradual loss into a dramatic reveal. The STEP 1 trial ran 68 weeks. Most visible results in studies emerged after 12 to 20 weeks. Second, individual variation is enormous. Response rates in trials showed some participants losing over 20% body weight while others lost under 5%. A single before-and-after doesn't tell you where you'll land on that distribution. Third, the compounded semaglutide question is real and unresolved. Many people accessing semaglutide right now are using compounded versions from 503A or 503B pharmacies, which are not FDA-approved and are not equivalent to Wegovy or Ozempic. FormBlends does not make equivalency claims between compounded and branded semaglutide. The FDA has flagged this issue repeatedly. Transformation videos almost never disclose which formulation was used.

What should you actually know?

Semaglutide is a legitimate, well-studied medication with meaningful clinical benefit for people with obesity or weight-related health conditions. A body mass index of 30 or higher, or 27 with at least one weight-related comorbidity, is the standard prescribing threshold for Wegovy. That clinical context matters. This is not a supplement. It's a weekly subcutaneous injection that works through GLP-1 receptor agonism, slowing gastric emptying and reducing appetite signaling. Side effects, including nausea, vomiting, constipation, and in rare cases pancreatitis, are real and require medical supervision. If you're seeing these transformation videos and considering semaglutide, the conversation needs to happen with a licensed clinician who can review your full medical history, not with a comment section. Results like those shown in viral videos are possible. They are not guaranteed, and they typically don't persist after discontinuation without ongoing treatment or significant lifestyle intervention.